Biosyntia raises €11.5 million for biobased biotin


In Denmark, precision fermentation firm Biosyntia has closed an €11.5 million (US$11.6 million) Series B funding round that it will use to launch the world’s first biobased vitamin B7. 

ECBF lead led the funding, with participation from existing investors Sofinnova Partners and Novo Seeds, the early-stage investment and company creation team of Novo Holdings A/S. The investment will allow Biosyntia to enter the production phase of its natural and sustainable active ingredients, including a biobased biotin (vitaminB7), for use in dietary supplements, food, and beauty products.

 “The investment enables us to finally offer customers the first and only natural and sustainable alternative to what is available for them today,” says Martin Plambech, CEO of Biosyntia, in a press statement. Biosyntia already has several commercial partnerships, including collaborations with Givaudan and WACKER.